No beneficial effects of amantadine in treatment of chronic hepatitis C patients

Autor: Peter Houben, Nancy A.M. Van Ooteghem, J.M. Vrolijk, Peter D. Siersema, Bart van Hoek, Rob J. Lieverse, Karel J. van Erpecum, Hanneke van Soest, Ger H. Koek, Greet J. Boland, Marguerite E.I. Schipper, Richard A. de Vries, Peter J. van der Schaar, Joost P.H. Drenth, Annet van der Sluys Veer
Přispěvatelé: Interne Geneeskunde, RS: NUTRIM - R2 - Gut-liver homeostasis
Jazyk: angličtina
Rok vydání: 2010
Předmět:
Adult
Male
medicine.medical_specialty
Genotype
Hepatitis C virus
Hepacivirus
Interferon alpha-2
medicine.disease_cause
Placebo
Antiviral Agents
Gastroenterology
Drug Administration Schedule
Polyethylene Glycols
chemistry.chemical_compound
Internal medicine
Ribavirin
Amantadine
medicine
Humans
Molecular gastro-enterology and hepatology [IGMD 2]
Amantadine Hepatitis C PEG-interferon Ribavirin placebo-controlled trial treatment-naive patients alpha-2a plus ribavirin initial treatment virus-infection randomized trial triple therapy double-blind influenza-a interferon
Interferon alfa
Hepatology
biology
business.industry
Interferon-alpha
Hepatitis C
Hepatitis C
Chronic
Middle Aged
Viral Load
medicine.disease
biology.organism_classification
Recombinant Proteins
Intention to Treat Analysis
Surgery
chemistry
Drug Therapy
Combination
Female
business
Viral load
medicine.drug
Zdroj: Digestive and Liver Disease, 42, 7, pp. 496-502
Digestive and Liver Disease, 42, 496-502
Digestive and Liver Disease, 42(7), 496-502
Digestive and Liver Disease, 42(7), 496-502. Elsevier Science
ISSN: 1590-8658
Popis: Contains fulltext : 89730.pdf (Publisher’s version ) (Closed access) BACKGROUND: Benefit of adding amantadine to antiviral therapy for hepatitis C is controversial. AIMS: We aimed to examine whether such policy enhances sustained viral response in treatment-naive patients. METHODS: 297 naive hepatitis C patients were randomized for treatment with amantadine 200mg or placebo, combined with weight-based ribavirin and 12-day high-dose interferon alpha-2b induction therapy, followed by PEG-interferon alpha-2b (1.5 microg/kg/week up to 26 weeks and thereafter, 1.0 microg/kg/week until week 52). Treatment was discontinued if hepatitis C virus (HCV) RNA was positive at week 24. RESULTS: 49% of patients were (former) drug users. Genotype 1 occurred in 45%, high viral load in 70% and severe fibrosis/cirrhosis in 32%, without differences between amantadine or placebo groups. 90 patients prematurely discontinued treatment, mainly because of grade 3 or 4 toxicity. Intention-to-treat analysis revealed sustained viral response in 47% and 51% of amantadine and placebo groups (p=0.49). Amantadine did not enhance sustained viral response in patients with genotype 1 or high viral load nor did it improve primary non-response, breakthrough or relapse rates. Genotype non-1 and lower pre-treatment gamma GT levels were independent predictors for sustained viral response. CONCLUSION: Adding amantadine to antiviral therapy of previously untreated chronic hepatitis C patients has no beneficial effects. 01 juli 2010
Databáze: OpenAIRE
Externí odkaz: